Theracryf Plc (TCF.L) Research

Theracryf Plc operates as a clinical-stage biotechnology firm, dedicated to advancing treatments for oncological diseases and various brain disorders affecting behavior. Its primary therapeutic asset, SFX-01, is currently progressing through Phase II clinical trials for metastatic breast cancer. Additionally, SFX-01 is in Phase I trials for neurodevelopmental conditions and glioblastoma, and is undergoing preclinical investigation for rhabdomyosarcoma. The company's pipeline also includes an orexin 1 antagonist, which is in the late preclinical stage for addressing addiction and anxiety, alongside an atypical dopamine transporter inhibitor (DAT) at a similar development stage, targeting fatigue and narcolepsy. Incorporated in 2014 and headquartered in Nether Alderley, United Kingdom, the company rebranded from Evgen Pharma plc to Theracryf Plc in April 2024.

Market snapshot

Symbol
TCF.L
Price
$0.24
Day change
0.00%
Market cap
$5.1M
P/E ratio
-4.70x
52-week range
0.175-0.3
Sector
Healthcare
Industry
Biotechnology
Next earnings
in 1 day

Peer companies

  • Chill Brands Group PLC (CHLL.L)
  • CRISM Therapeutics Corporation (CRTX.L)
  • Feedback plc (FDBK.L)
  • MyHealthChecked PLC (MHC.L)
  • N4 Pharma Plc (N4P.L)
  • Oxford BioDynamics Plc (OBD.L)
  • Proteome Sciences plc (PRM.L)
  • Roquefort Therapeutics plc (ROQ.L)

Open Theracryf Plc (TCF.L) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.